U.S. Stock Futures Slide as Iran Conflict and Inflation Fears Rattle Wall Street 
Jeff Bezos Eyes $100 Billion Fund to Transform Manufacturing With AI 
Sinopec Posts 36.8% Net Profit Drop in 2025 Amid Weak Petrochemical Margins and Energy Transition Pressures 
J.P. Morgan Now Expects Two ECB Rate Hikes Amid Inflation Pressures 
Oil Prices Hold Steady Amid Middle East Escalation and Sanctions Relief 
Xiaomi Shares Drop After SU7 Launch as Margin Concerns Weigh on Investors 
European Stocks Tumble as Iran-Strait of Hormuz Crisis Rattles Global Markets 
NVIDIA's Feynman AI Chip May Face Redesign Amid TSMC Capacity Crunch 
Trump Signals End of U.S. Military Campaign Against Iran as Markets Rally 
Global Markets Reel as Middle East Tensions Escalate Energy Fears 
Palantir's Maven AI Earns Pentagon "Program of Record" Status, Reshaping Military AI Strategy 
Iran War Fears Send Oil Prices Surging as U.S. Weighs Ground Troop Deployment 
Paraguay Central Bank Holds Interest Rate at 5.5% Amid Slowing Growth 
Finnair Orders 18 Embraer E195-E2 Jets in Landmark Fleet Overhaul 
EA's $15B Debt Offering Draws $25B in Investor Demand Amid Credit Market Turmoil 
Global Markets Tumble as US-Iran Tensions Escalate, Oil Surges 
U.S. Appeals Court Strikes Down FTC Order Against TurboTax "Free" Advertising 
Samsung Biologics is now confirmed to produce Moderna’s COVID-19 vaccines in South Korea. The biotechnology company headquartered in Incheon is said to be working to hasten preparations and begin the production of the shots in the second half of this year.
Confirmation of the vaccine production deal
The Korea Herald reported that Samsung Biologics is preparing its drug manufacturing facility in Songdo, Incheon. This is said to be one of the largest in the world and it is here where the biotech firm will be handling the filling and finishing process of Moderna vaccine production. To be more specific, the mRNA-1273 which is the American pharmaceutical company’s messenger-RNA-based COVID-19 shot.
The Samsung and Moderna agreement was officially signed and this was witnessed by South Korean President Moon Jae In looking. The deal is actually part of the Korean-US vaccine partnership that was one of the agendas at the recent summit that was held in the U.S. last week.
The agreement between Samsung Biologics and Moderna
Samsung Biologics will be filling up vials and packaging them for sale and distribution. The main vaccine content will be coming directly from Moderna and Lonza, its Swiss production partner, and the overall finishing process will be done in Korea.
"This vaccine is paramount to people around the world in the fight against the COVID-19 pandemic, and we truly appreciate our client Moderna for entrusting and choosing to partner with Samsung Biologics for the fill and finish of this important vaccine," Samsung Biologics CEO, John Rim, said in a press release."Due to the high level of urgency in supplying the vaccine to the global population, we have set immediate action plans and schedule to make mRNA-1273 available for commercial distribution in the early second half of 2021."
On the other hand, Moderna’s chief technical operations and quality officer, Juan Andres, said that they are pleased to team up with Samsung Biologics for the fill and finish production. He explained that this arrangement will help them continue to boost their manufacturing capacity outside of the U.S. as they remained committed to beating COVID-19.
Meanwhile, South Korean government officials gladly welcomed the partnership as this is a big opportunity for the country to scale up and be a global factory of vaccines for COVID-19.
